Blood sample
BiologicalBlood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
NCT Number: NCT05388838
Uveitis is an inflammation of the uvea, an ocular tunic comprising the iris, ciliary body and choroid. This inflammation can also involve other tissues such as the retina, the optic nerve and the aqueous humor. These diseases can result in significant vision loss and account for 10% of all blindness in developed countries, and up to 25% in developing countries. The main difficulty in this pathology is to make the etiological diagnosis, which then allows a specific treatment of the disease. The main etiologie are inflammatory or infectious (sarcoidosis, tuberculosis) but other cancerous etiologies are possible and are of more complicated diagnosis.
Vitreoretinal lymphoma is a subtype of central nervous system lymphoma, which is generally associated with a poor prognosis. It is a diffuse non-Hodgkin's lymphoma, with large B cells. It can be primary ocular (Primary Intra-Ocular Lymphoma - LIOP), without brain involvement, but can also be secondary to central nervous system involvement, which explains the poor prognosis of the disease. Approximately 50-90% of LIOP develop brain involvement within 1-2 years of diagnosis, which encourages early diagnosis to avoid brain involvement as much as possible.
The main obstacle to rapid diagnosis is the difficulty of identifying LIOP. Indeed, the clinical symptoms of this rare disease are often identical to classical uveitis, and the diagnostic means to detect it are invasive and require a trained ophthalmologist and hematologist team. LIOP diagnostic tests are often delay in the management of uveitis and lead to diagnostic erraticity that can last between 4 to 40 months.
The INSERM U1183 unit is developing a diagnostic technology for lymphomas based on the analysis of blood NK cells and their phenotypes including those acquired by trogocytosis (WO/2016/005548).
A rapid, simple, minimally invasive LIOP test using this technology could therefore be propose to all patients presenting with uveitis and whose clinical criteria could match those of LIOP.
The research hypothesis is : Could the diagnostic wandering of patients with primary intraocular lymphoma be reduced by a rapid blood test for NK cell phenotype of patients with uveitis? Following a simple blood test, a rapid LIOP test, using this diagnostic technology, could therefore be proposed to all patients with uveitis and clinical criteria (age, intermediate and posterior location of the uveitis) corresponding to those of LIOP.
The primary objective of this study is to compare the phenotype of circulating NK cells of patient with untreated intraocular lymphoma versus the phenotype of patient with non-cancerous uveitis.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Service d'Hématologie Clinique, Hôpital Lyon Sud, Lyon, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
GENERAL CRITERIA
SPECIFIC CRITERIA
Exclusion criteria
SPECIFIC CRITERIA
Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
Time frame: through study completion, an average of 1 year
mesure by Flow Cytometry
Time frame: through study completion, an average of 1 year
mesure by Flow Cytometry
Contact information is provided by the study sponsor or research team.
Christelle SZATANEK, MsC
CONTACT
4 26 73 27 24 ext. +33
Thibaud MATHIS, Dr
CONTACT
4 26 10 93 22 ext. +33
Hospices Civils de Lyon
Other
Screening for Oculocerebral Lymphoma by Identifying the Phenotype Carried by Circulating NK Cells in Patients with Uveitis
Acronym: DeLPHy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07547995
Eye Diseases, Uveal Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06974162
Aqueous Humor, Eye Diseases
London, United Kingdom
View Trial DetailsNCT07518134
Eye Diseases, Uveal Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT06273748
Eye Diseases, Uveal Diseases
Kansas City, Kansas, United States
View Trial Details